CytoSorbents posts investor presentation outlining blood purification products, DrugSorb-ATR regulatory path

CytoSorbents Corporation

CytoSorbents Corporation

CTSO

0.00
  • CytoSorbents highlighted 2025 sales of $37.1 million, citing 71% gross margin and a “razorblade” recurring-consumables model.
  • Management flagged a target for operating cash flow breakeven in 2H 2026, positioning that as a step toward profitability.
  • CytoSorb was described as CE-marked in Europe, distributed in more than 70 countries, with cumulative use exceeding 300,000 treatments.
  • DrugSorb-ATR was presented as an investigational, FDA Breakthrough Designated device, with a planned US De Novo submission in late 2026 or early 2027.
  • Strategic partnerships were cited with Fresenius Medical Care, B. Braun, Terumo Cardiovascular; US government support totaled about $50 million in non-dilutive funding.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.